Skip to content

Elisabet Cuyàs

3 papers in the library · 135 citations · publishing 2008-2012

Papers

Sort Most recent Most cited

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

PLoS One October 24, 2012 Ricardo Pardo‐lozano, M. Farré, Samanta Yubero‐lahoz et al. 67 citations

The synthetic psychostimulant MDMA (±3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have satisfactorily evaluated the factors contributing to...

5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.

Addiction Biology January 2010 Rocío Martín‐Santos, Marta Torrens, Sandra Poudevida et al.

A 3-year longitudinal prospective study was conducted to compare the incidence of substance use disorders (SUD) and non-substance use disorders (NSUD) among ecstasy users and two control groups: one of cannabis users and the other of non-drug users. The 5-HTTLPR polymorphism related to NSUD was also studied. A total of 94 subjects were included: 37 ecstasy users, 23 cannabis users and 34...

The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans

Journal of Clinical Psychopharmacology September 12, 2008 Brian O’Mathúna, Magı́ Farré, Amin Rostami‐hodjegan et al. 68 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a widely abused substituted amphetamine. MDMA is predominantly O-demethylenated in humans by cytochrome P450 isoforms 2D6 and 1A2 (CYP2D6 and CYP CYP1A2, respectively). MDMA is also a mechanism-based inhibitor of CYP2D6. A controlled clinical trial was conducted in 15 healthy male subjects whereby a probe drug, dextromethorphan (DEX), was...